| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/10/2006 | CA2601773A1 Compositions of unconjugated estrogens and methods for their use |
| 08/10/2006 | CA2601762A1 Dosage forms providing controlled and immediate release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors |
| 08/10/2006 | CA2601740A1 Use of tyrosine kinase inhibitors for the treatment of chronic rhinosinusitis |
| 08/10/2006 | CA2597219A1 Contact drug delivery system |
| 08/10/2006 | CA2597212A1 11a, 12-derivatives of tetracycline compounds |
| 08/10/2006 | CA2597092A1 Aqueous gel formulations containing immune reponse modifiers |
| 08/10/2006 | CA2596993A1 Optically active tetrahydronaphthalene derivative |
| 08/10/2006 | CA2596973A1 Raf inhibitor compounds and methods |
| 08/10/2006 | CA2596967A1 Thiazolidinones for use as inhibitors of polo-like kinase (plk) |
| 08/10/2006 | CA2596959A1 New uses of dinucleotide polyphosphate derivatives |
| 08/10/2006 | CA2596933A1 Devices for delivering agents to a vaginal tract |
| 08/10/2006 | CA2596854A1 Imidazole derivatives |
| 08/10/2006 | CA2596851A1 Agent for prevention/treatment of disease caused by acyclovir-resistant herpesvirus |
| 08/10/2006 | CA2596850A1 Medicament for genital herpes |
| 08/10/2006 | CA2596799A1 Amine derivative containing compositions and methods for the treatment of viral infections related to the etiology of cancer |
| 08/10/2006 | CA2596759A1 Local treatment of neurofibromas |
| 08/10/2006 | CA2596754A1 Crystalline 1h-imidazo[4,5-b]pyridin-5-amine,7-[5-[(cyclohexylmethylamino)-methyl]-1h-indol-2-yl]-2-methyl, sulfate (1:1), trihydrate and its uses for the treatment of inflammatory, autoimmune and proliferative diseases and disorders |
| 08/10/2006 | CA2596736A1 Tricyclic cytoprotective compounds |
| 08/10/2006 | CA2596730A1 Adjuvanting material comprising pam2cys or pam3cys covalently linked to a metal chelating group |
| 08/10/2006 | CA2596714A1 Method for treating gefitinib resistant cancer |
| 08/10/2006 | CA2596686A1 Preventive or therapeutic agent for herpesvirus-related disease |
| 08/10/2006 | CA2596639A1 Inhibitors of diacylglycerol acyltransferase (dgat) |
| 08/10/2006 | CA2596634A1 Isolation of atraric acid, synthesis of atraric acid derivatives, and use of atraric acid and the derivatives thereof for the treatment of benign prostatic hyperplasia, prostate carcinoma and spinobulbar muscular atrophy |
| 08/10/2006 | CA2596618A1 Isolation of n-butylbenzenesulfonamide, synthesis of benzenesulfonamide derivatives, and use of n-butylbenzenesulfonamide and benzenesulfonamide derivatives for treating benign prostatic hyperplasia and/or prostate carcinoma |
| 08/10/2006 | CA2596612A1 Novel adenosine a3 receptor modulators |
| 08/10/2006 | CA2596588A1 Nucleic acid silencing of huntington's disease gene |
| 08/10/2006 | CA2596480A1 Compounds and methods for modulating communication and virulence in quorum sensing bacteria |
| 08/10/2006 | CA2596444A1 1-acylamino-2-hydroxy-3-amino-w-arylalkanes as renin inhibitors |
| 08/10/2006 | CA2596428A1 Glucuronidated nebivolol_metabolites |
| 08/10/2006 | CA2596426A1 Pharmaceutical composition comprising hydroxylated nebivolol |
| 08/10/2006 | CA2596424A1 Inhibitors of e1 activating enzymes |
| 08/10/2006 | CA2596368A1 Diketo acids with nucleobase scaffolds: anti-hiv replication inhibitors targeted at hiv integrase |
| 08/10/2006 | CA2596358A1 Aqueous gel formulations containing 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine |
| 08/10/2006 | CA2596355A1 Tumor necrosis factor inhibitors |
| 08/10/2006 | CA2596332A1 Anti-t cell and autoantigen treatment of autoimmune disease |
| 08/10/2006 | CA2596210A1 Combination therapies using hdac inhibitors |
| 08/10/2006 | CA2596189A1 Dosage forms of active ingredients containing hydroxystilbene for treating menopausal complaints |
| 08/10/2006 | CA2596186A1 Use of active ingredients containing hydroxystilbene for preventing and/or treating osteoporosis |
| 08/10/2006 | CA2596178A1 Method for producing a drug extract that contains hydroxystilbene |
| 08/10/2006 | CA2596171A1 Use of an active ingredient combination that contains hydroxystilbene for preventing and/or treating diseases |
| 08/10/2006 | CA2596142A1 Adenosine analogs useful as anti-bacterial and anti-protozoan agents |
| 08/10/2006 | CA2596026A1 .beta.-cyclodextrin derivatives as antibacterial agents |
| 08/10/2006 | CA2595987A1 1-h-pyrrole-2-carboxamides and imidazole-5-carboxamides and use thereof as fak, kdr and tie2 kinase modulators for the treatment of cancer |
| 08/10/2006 | CA2595979A1 Method for the production of a tamper-proof form of administration |
| 08/10/2006 | CA2595860A1 Anti-inflammatory supplement compositions and regimens to reduce cardiovascular disease risks |
| 08/10/2006 | CA2595835A1 Chemical compounds |
| 08/10/2006 | CA2595834A1 Pyrazolylaminopyridine derivatives useful as kinase inhibitors |
| 08/10/2006 | CA2595801A1 Multimers of pyrimidinone derivatives and their use as human neutrophil elastase inhibitors |
| 08/10/2006 | CA2595790A1 Rnai-mediated inhibition of ocular hypertension targets |
| 08/10/2006 | CA2595789A1 Compounds and compositions as ppar modulators |
| 08/10/2006 | CA2595786A1 Compositions and methods for treating fibrotic disorders |
| 08/10/2006 | CA2595772A1 Systems and methods for delivery of peritoneal dialysis (pd) solutions |
| 08/10/2006 | CA2595770A1 Formulations and dosing regimen for ppar-alpha modulators |
| 08/10/2006 | CA2595678A1 Rnai-mediated inhibition of ocular targets |
| 08/10/2006 | CA2595409A1 Oral dosage form comprising rosiglitazone |
| 08/10/2006 | CA2595252A1 Novel 6-pyridylphenanthridines |
| 08/10/2006 | CA2594845A1 Cyclohexylamides as dopamine d3 , d2 and 5ht1a antagonists |
| 08/10/2006 | CA2594674A1 Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds |
| 08/10/2006 | CA2594505A1 Imines as ion channel modulators |
| 08/10/2006 | CA2594466A1 Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
| 08/10/2006 | CA2594022A1 Process for producing polypeptide mixtures using hydrogenolysis |
| 08/10/2006 | CA2593858A1 Antidiabetic bicyclic compounds |
| 08/10/2006 | CA2593857A1 Amino-pyridines as inhibitors of .beta.-secretase |
| 08/10/2006 | CA2593854A1 Organic compounds |
| 08/10/2006 | CA2593788A1 Antidiabetic bicyclic compounds |
| 08/10/2006 | CA2593749A1 Classes of compounds that interact with integrins |
| 08/10/2006 | CA2593550A1 Compounds for inflammation and immune-related uses |
| 08/10/2006 | CA2593084A1 Use of diindolylmethane-related indoles for the treatment and prevention of respiratory syncytial virus associated conditions |
| 08/10/2006 | CA2593043A1 Drug delivery materials made by sol/gel technology |
| 08/10/2006 | CA2589328A1 Multicyclic bis-amide mmp inhibitors |
| 08/10/2006 | CA2588480A1 Amorphous tacrolimus and preparation thereof |
| 08/10/2006 | CA2566809A1 Substituted aryl acylthioureas and related compounds; inhibitors of viral replication |
| 08/09/2006 | EP1688496A2 Regulation of human P2Y1-like G protein-coupled receptor |
| 08/09/2006 | EP1688432A1 Igm high concentration stabilized solution |
| 08/09/2006 | EP1688430A2 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 08/09/2006 | EP1688425A2 Cyclic salen-metal compounds as scavengers for oxygen radicals and useful as antioxidants in the treatment and prevention of diseases |
| 08/09/2006 | EP1688420A1 5-5-membered fused heterocyclic compound and use thereof as hcv polymerase inhibitor |
| 08/09/2006 | EP1688419A1 Novel compound and medicinal composition |
| 08/09/2006 | EP1688418A2 Chemokine receptor antagonists and methods of use thereof |
| 08/09/2006 | EP1688416A1 Substituted heterocyclic compounds, their process of preparation and pharmaceutical compositions containing them |
| 08/09/2006 | EP1688413A1 Benzoxazole derivatives for the prophylaxis and treatment of inflammatory bowel diseases |
| 08/09/2006 | EP1688412A2 Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands |
| 08/09/2006 | EP1688410A1 Crystal of phenylalanine derivative and process for producing the same |
| 08/09/2006 | EP1688409A1 Vitamin d-derived monohalogenovinyl compounds |
| 08/09/2006 | EP1688408A2 Vanilloid receptor ligands and their use in treatments |
| 08/09/2006 | EP1688169A1 Method for producing fine organic compound particles |
| 08/09/2006 | EP1688161A1 Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis |
| 08/09/2006 | EP1688156A2 A filtrate composition for use in dialysis via the colon |
| 08/09/2006 | EP1688149A1 Paste formulations comprising silica |
| 08/09/2006 | EP1688148A1 Combination treatment using exendin-4 and thiazolidinediones |
| 08/09/2006 | EP1688147A1 Methods Related to Immunostimulatory Nucleic Acid-Induced Interferon |
| 08/09/2006 | EP1688144A1 Ophthalmic compositions containing quinolone-antibiotics |
| 08/09/2006 | EP1688143A2 Niacin-containing substained-release tablets and kits |
| 08/09/2006 | EP1688142A1 Terfenadine carboxylate and the treatment of dermal irritation |
| 08/09/2006 | EP1688141A1 The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome |
| 08/09/2006 | EP1688140A1 Lipometabolism improver containing pine bark extract |
| 08/09/2006 | EP1688139A1 Creatine ester pronutrient compounds and formulations |
| 08/09/2006 | EP1688138A1 Receptor function regulating agent |
| 08/09/2006 | EP1688137A1 SPM 927 for add-on therapy of schizophrenia |
| 08/09/2006 | EP1688136A1 Hydrophilic bioquinone compounds, process for their preparation and use |